全反式维甲酸、三氧化二砷联合吉妥珠单抗治疗急性早幼粒细胞白血病的长期结局
在3项连续前瞻性临床试验中,187例新诊断急性早幼粒细胞白血病患者接受全反式维甲酸联合三氧化二砷方案,高危患者及诱导期间出现白细胞增多的低危患者加用吉妥珠单抗。完全缓解率96%,中位随访47.6个月,5年无事件生存率85%、无病生存率96%、总生存率88%,仅7例复发。
要点
- 187例患者完全缓解率96%,高危52/54、低危127/133。
- 中位随访47.6个月,5年无事件生存率85%、无病生存率96%、总生存率88%。
- 诱导死亡率4%,仅7例复发,1年后晚期血液学复发3例。
核心结论
- 本研究证实全反式维甲酸联合三氧化二砷方案(加或不加吉妥珠单抗)治疗新诊断急性早幼粒细胞白血病的缓解具有持久性。
研究设计与样本
- 研究在本机构3项连续前瞻性临床试验中治疗新诊断急性早幼粒细胞白血病患者,使用全反式维甲酸联合三氧化二砷方案,加或不加吉妥珠单抗。
- 共治疗187例患者,其中高危54例、低危133例。
- 诱导治疗:所有患者接受全反式维甲酸45 mg/m2每日联合三氧化二砷0.15 mg/kg每日;高危患者(白细胞计数>10×10^9/L)及诱导期间出现白细胞增多的低危患者加用吉妥珠单抗9 mg/m2第1天。
- 完全缓解后接受4个周期全反式维甲酸联合三氧化二砷巩固治疗。
主要发现
- 完全缓解率为96%(高危52/54,低危127/133)。
- 诱导死亡率为4%,仅7例复发。
- 低危患者中60例(45%)因白细胞增多需要吉妥珠单抗或伊达比星。
- 中位随访47.6个月,5年无事件生存率、无病生存率、总生存率分别为85%、96%、88%。
- 1年后晚期血液学复发3例;1年后死亡14例,其中12例与其它原因相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The combination of all-trans-retinoic acid (ATRA) plus arsenic trioxide (ATO) has been shown to be superior to ATRA plus chemotherapy in the treatment of standard-risk patients with newly diagnosed acute promyelocytic leukemia (APL). A recent study demonstrated the efficacy of this regimen with added gemtuzumab ozogamicin (GO) in high-risk patients. We examined the long-term outcome of patients with newly diagnosed APL treated at our institution on 3 consecutive prospective clinical trials, using the combination of ATRA and ATO, with or without GO. For induction, all patients received ATRA (45 mg/m2 daily) and ATO (0.15 mg/kg daily) with a dose of GO (9 mg/m2 on day 1) added to high-risk patients (white blood cell count, >10 × 109/L), as well as low-risk patients who experienced leukocytosis during induction. Once in complete remission, patients received 4 cycles of ATRA plus ATO consolidation. One hundred eighty-seven patients, including 54 with high-risk and 133 with low-risk disease, have been treated. The complete remission rate was 96% (52 of 54 in high-risk and 127 of 133 in low-risk patients). Induction mortality was 4%, with only 7 relapses. Among low-risk patients, 60 patients (45%) required either GO or idarubicin for leukocytosis. Median duration of follow-up was 47.6 months. The 5-year event-free, disease-free, and overall survival rates are 85%, 96%, and 88%, respectively. Late hematological relapses beyond 1 year occurred in 3 patients. Fourteen deaths occurred beyond 1 year; 12 were related to other causes. This study confirms the durability of responses with this regimen.
引用
- Abaza Y, Kantarjian H, Garcia-Manero G, et al. Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab. Blood. 2016. PMID: 28003274. doi:10.1182/blood-2016-09-736686
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。